Denmark’s Novo Nordisk has adjusted its annual revenue and profit forecasts downward following weaker-than-expected sales of its weight-loss drug Wegovy in the United States. The company, which became Europe’s most
Denmark’s Novo Nordisk has adjusted its annual revenue and profit forecasts downward following weaker-than-expected sales of its weight-loss drug Wegovy in the United States. The company, which became Europe’s most






